Runda Medical disclosed its earnings forecast, expecting a net loss attributable to the parent company of 78.6 million to 94.3 million yuan for the first half of 2026, compared with a loss of 121 million yuan in the same period last year. The net loss after deducting non-recurring items is expected to be 72.2 million to 86.6 million yuan, compared with a loss of 134 million yuan a year earlier. The company's main business includes comprehensive services and industrial segments. The loss is mainly due to the deepening implementation of policies such as centralized procurement of in-vitro diagnostic products, which led to a year-on-year decline in revenue scale, although the decline has narrowed compared with the same period last year. At the same time, fixed expenses such as employee compensation, depreciation, and amortization could not be reduced simultaneously. The company has taken cost-cutting and efficiency-enhancing measures, and operations are gradually improving. The net loss margin has narrowed compared with the same period last year, and net cash flow from operating activities during the reporting period increased by more than 50 percent compared with the same period last year.
Shanghai Runda Med Tech CoLoss due to deepening centralized procurement policy for in-vitro diagnostic products, reducing revenue.